EH

Edara Hari Babu

Active Director Director DIN 09623037
DIN 09623037 First appointment May 2022 Primary industry Chemicals
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2022
Shareholding value •••• Premium profile

About Edara Hari Babu

Data last updated:

Edara Hari Babu is a Director at Strigine Pharmaceuticals Private Limited (since 2022). The company operates in Chemicals. Strigine Pharmaceuticals Private Limited reported revenue of ₹94,422 (FY 2023).

DIN 09623037
Primary Designation Director
Industry Chemicals
First Appointment 25 May 2022
Oldest Company Age 6 yrs
Largest company Strigine Pharmaceuticals Private Limited · ₹94,422 (FY 2023)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director25 May 20222020₹94,422 (FY 2023)Active

Board colleagues of Edara Hari Babu

Directorship timeline

Open interactive timeline →
Strigine Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Edara Hari Babu

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Edara Hari Babu

Edara Hari Babu currently holds 1 directorship: Strigine Pharmaceuticals Private Limited (Director, since 25 May 2022, revenue ₹94,422 (FY 2023)).

Edara Hari Babu was first appointed on 25 May 2022 as Director at Strigine Pharmaceuticals Private Limited.

The current boards of Edara Hari Babu's companies include Srilakshmi Nannuri Suryanarayana Rao (Strigine Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available